Clinical Trials on Hereditary Angioedema - Type 2 in Japan

Total 402 results

Takeda

Recruiting

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)

Japan
Takeda

Recruiting

A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)

Japan
Shire

Completed

A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants

Hereditary Angioedema (HAE)

Japan
BioCryst Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan (APeX-J)

Hereditary Angioedema, HAE

Japan
Shire

Completed

Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
Takeda

Completed

A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema

Hereditary Angioedema

Japan
Shire
Takeda

Completed

FIRAZYR General Drug Use-Results Survey (Japan)

Hereditary Angioedema (HAE)

Japan
Shire

Completed

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
Takeda

Completed

Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema

Hereditary Angioedema

Japan
CSL Behring

Completed

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

Hereditary Angioedema

United States, Germany, Japan, Hungary, Canada, Netherlands, Israel
KalVista Pharmaceuticals, Ltd.

Recruiting

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Hereditary Angioedema

United States, Bulgaria, France, Greece, Israel, Netherlands, Spain, United Kingdom, Australia, Germany, South Africa, Slovakia, Austria, New Zealand, Romania, Canada, Japan
KalVista Pharmaceuticals, Ltd.

Completed

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Hereditary Angioedema

United States, Australia, Bulgaria, Canada, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, North Macedonia, Poland, Portugal, Puerto Rico, Romania, Slovakia, Spain, United Kingdom
KalVista Pharmaceuticals, Ltd.

Recruiting

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Hereditary Angioedema

United States, Bulgaria, France, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, North Macedonia, Poland, Spain, United Kingdom, Australia, Germany, South Africa, Austria, Portugal, Slovakia, Romania, Canada, Saudi Arabia, Japa...
CSL Behring

Active, not recruiting

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Hereditary Angioedema

Australia, Canada, United States, New Zealand, Germany, Hong Kong, Netherlands, Taiwan, Czechia, Israel, Hungary, Japan, Russian Federation, Spain
CENTOGENE GmbH Rostock

Completed

Epidemiological Analysis for Hereditary Angioedema Disease (EHA)

Abdominal Pain | Functional Abdominal Pain

United Kingdom, Germany, Turkey, Poland, Italy, Japan
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Angioedema

United States, Spain, Netherlands, Hungary, Italy, Canada, Germany, France, Japan, Poland
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Angioedema

United States, France, Netherlands, Spain, Hungary, Italy, Canada, Poland, Japan, Germany
Daiichi Sankyo Co., Ltd.

Completed

A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Type2 Diabetes Mellitus

Japan
Daiichi Sankyo Co., Ltd.

Completed

Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Monotherapy Study of MP-513 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"

Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Type 2 Diabetes Mellitus

Japan
Saitama Medical University

Completed

Relationship Between Body Weight and Glycohemoglobin

Type 2 Diabetes Mellitus

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin

Type 2 Diabetes Mellitus

Japan
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Nagaoka Red Cross Hospital
Kurume University

Unknown

DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"

Type 2 Diabetes Mellitus

Japan
Novartis Pharmaceuticals

Completed

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Hoffmann-La Roche

Terminated

Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG

Diabetes

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (GAUDI)

Type 2 Diabetes Mellitus

Japan
Niigata Medical Center
Nagaoka Red Cross Hospital

Unknown

Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

Japan
Sanofi

Completed

Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride

Type 2 Diabetes Mellitus

Japan
Kanazawa University

Unknown

Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases

Type 2 Diabetes Mellitus | Chronic Liver Disease

Japan
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Eli Lilly and Company

Completed

A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

Type 2 Diabetes

Japan
Astellas Pharma Inc

Completed

A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Kyowa Kirin Co., Ltd.

Completed

A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus

Diabetes

Japan
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea

Surveillance

Japan
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides

Surveillance

Japan
AstraZeneca

Completed

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients (JMAD)

Type 2 Diabetes

Japan

3

Subscribe